Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Clinical Relevance of Topical Antibiotic Use in Coselecting for Multidrug-Resistant Staphylococcus aureus: Insights from In Vitro and Ex Vivo Models
Nong, Y; Taiaroa, G; Pasricha, S; Guerillot, R; Monk, IR; Baines, SL; Carter, GP; Howden, BP; Williamson, DA
(2021), Antimicrob. Agents Chemother.
DOI: 10.1128/AAC.02048-20
Infrared Based Saliva Screening Test for COVID-19
Wood, BR; Kochan, K; Bedolla, DE; Salazar-Quiroz, N; Grimley, SL; Perez-Guaita, D; Baker, MJ; Vongsvivut, J; Tobin, MJ; Bambery, KR; Christensen, D; Pasricha, S; Eden, AK; Mclean, A; Roy, S; Roberts, JA; Druce, J; Williamson, DA; McAuley, J; Catton, M; Purcell, DFJ; Godfrey, DI; Heraud, P
(2021), Angew. Chem.-Int. Edit., 17102-17107
The Causal Interpretation of Overall Vaccine Effectiveness in Test-Negative Studies
Feng, S; Sullivan, SG; Tchetgen, EJT; Cowling, BJ
(2021), Am. J. Epidemiol., 1993-2014
DOI: 10.1093/aje/kwab101
Scoping review: hotspots for COVID-19 urological research: what is being published and from where?
Qu, LG; Perera, M; Lawrentschuk, N; Umbas, R; Klotz, L
(2021), World J. Urol., 3151-3160
A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer
Holmes, A; Kelly, BD; Perera, M; Eapen, RS; Bolton, DM; Lawrentschuk, N
(2021), World J. Urol., 297-306
Ga-68-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial
Bowden, P; See, AW; So, K; Lawrentschuk, N; Moon, D; Murphy, DG; Rao, R; Crosthwaite, A; King, D; Haxhimolla, H; Grummet, J; Ruljancich, P; Gyomber, D; Landau, A; Campbell, N; Frydenberg, M; Smyth, LML; Nolan, S; Gwini, SM; McKenzie, DP
(2021), World J. Urol., 4117-4125
Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer
Degeling, K; Corcoran, NM; Pereira-Salgado, A; Hamid, AA; Siva, S; IJzerman, MJ
(2021), Value Health, 1737-1745
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey
Fine, SW; Trpkov, K; Amin, MB; Algaba, F; Aron, M; Baydar, DE; Beltran, AL; Brimo, F; Cheville, JC; Colecchia, M; Comperat, E; Costello, T; da Cunha, IW; Delprado, W; DeMarzo, AM; Giannico, GA; Gordetsky, JB; Guo, CC; Hansel, DE; Hirsch, MS; Huang, JT; Humphrey, PA; Jimenez, RE; Khani, F; Kong, MX; Kryvenko, ON; Kunju, LP; Lal, P; Latour, M; Lotan, T; Maclean, F; Magi-Galluzzi, C; Mehra, R; Menon, S; Miyamoto, H; Montironi, R; Netto, GJ; Nguyen, JK; Osunkoya, AO; Parwani, A; Pavlovich, CP; Robinson, BD; Rubin, MA; Shah, RB; So, JS; Takahashi, H; Tavora, F; Tretiakova, MS; True, L; Wobker, SE; Yang, XMJ; Zhou, M; Zynger, DL; Epstein, JI
(2021), Urol. Oncol.-Semin. Orig. Investig.
Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
Anderson, E; Smyth, LML; O'Sullivan, R; Ryan, A; Lawrentschuk, N; Grummet, J; See, AW
(2021), Transl. Androl. Urol., 3591-3603
DOI: 10.21037/tau-21-508
Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review
Ong, S; O'Brien, J; Medhurst, E; Lawrentschuk, N; Murphy, D; Azad, A
(2021), Transl. Androl. Urol., 3918-3930
DOI: 10.21037/tau-20-1118
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer
McCoy, P; Mangiola, S; Macintyre, G; Hutchinson, R; Tran, B; Pope, B; Georgeson, P; Hong, MKH; Kurganovs, N; Lunke, S; Clarkson, MJ; Cmero, M; Kerger, M; Stuchbery, R; Chow, K; Haviv, I; Ryan, A; Costello, AJ; Corcoran, NM; Hovens, CM
(2021), Prostate Cancer Prostatic Dis., 1167-1180
Irreversible Electroporation for Prostate Cancer
Ong, S; Leonardo, M; Chengodu, T; Bagguley, D; Lawrentschuk, N
(2021), Life-Basel
DOI: 10.3390/life11060490
Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study
Furrer, MA; Kiss, B; Studer, UE; Wuethrich, PY; Gahl, B; Seiler, R; Roth, B; Bosshard, P; Thomas, BC; Burkhard, FC; Boxler, S; Thalmann, GN
(2021), J. Urol., 1629-1640
Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis
Papa, N; Perera, M; Murphy, DG; Lawrentschuk, N; Evans, M; Millar, JL; Bolton, D
(2021), J. Med. Imag. Radiat. Oncol., 649-654
Predictors for Perioperative Blood Transfusion in Patients Undergoing Open Cystectomy and Urinary Diversion and Development of a Nomogram: An Observational Cohort Study
Engel, D; Beilstein, CM; Jerney, P; Furrer, MA; Burkhard, FC; Loffel, LM; Wuethrich, PY
(2021), J. Clin. Med.
DOI: 10.3390/jcm10132797
Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy
Cmero, M; Kurganovs, NJ; Stuchbery, R; McCoy, P; Grima, C; Ngyuen, A; Chow, K; Mangiola, S; Macintyre, G; Howard, N; Kerger, M; Dundee, P; Ruljancich, P; Clarke, D; Grummet, J; Peters, JS; Costello, AJ; Norden, S; Ryan, A; Parente, P; Hovens, CM; Corcoran, NM
(2021), JCO Precis. Oncol., 1048-1059
DOI: 10.1200/PO.20.00337
The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer
Bagguley, D; Ong, S; Buteau, JP; Koschel, S; Dhiantravan, N; Hofman, MS; Emmett, L; Murphy, DG; Lawrentschuk, N
(2021), Future Oncol., 2225-2241
The application of theranostics in different stages of prostate cancer
Alghazo, O; Eapen, R; Koschel, S; Cumberbatch, M; Buteau, J; Loh, R; Lawrentschuk, N; Murphy, DG
(2021), Future Oncol., 3637-3644
WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cm(3) and 80-150-cm(3) Prostates
Nguyen, DD; Barber, N; Bidair, M; Gilling, P; Anderson, P; Zorn, KC; Badlani, G; Humphreys, M; Kaplan, S; Kaufman, R; So, A; Paterson, R; Goldenberg, L; Elterman, D; Desai, M; Lingeman, J; Roehrborn, C; Bhojani, N
(2021), Eur. Urol. Open Sci., 21-28
Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review
Degeling, K; Pereira-Salgado, A; Corcoran, NM; Boutros, PC; Kuhn, P; IJzerman, MJ
(2021), Eur. Urol. Open Sci., 77-87
Routine Preoperative Bone Scintigraphy Has Limited Impact on the Management of Patients with Invasive Bladder Cancer
Furrer, MA; Grueter, T; Bosshard, P; Vartolomei, MD; Kiss, B; Thalmann, GN; Roth, B
(2021), Eur. Urol. Focus, 1052-1060
Prostate-specific Antigen Screening Using the Traditional Cutoff of 3 ng/ml: Pro
Lawrentschuk, N
(2021), Eur. Urol. Focus, 499-500
Preclinical Evaluation of the Versius Surgical System, a New Robot-assisted Surgical Device for Use in Minimal Access Renal and Prostate Surgery
Thomas, BC; Slack, M; Hussain, M; Barber, N; Pradhan, A; Dinneen, E; Stewart, GD
(2021), Eur. Urol. Focus, 444-452
Long-term Outcomes of Cystectomy and Crossfolded Ileal Reservoir Combined with an Afferent Tubular Segment for Heterotopic Continent Urinary Diversion: A Longitudinal Single-centre Study
Furrer, MA; Kiss, B; Wuthrich, PY; Thomas, BC; Noser, L; Studer, UE; Burkhard, FC
(2021), Eur. Urol. Focus, 629-637
Functional Results, Complications Associated with the Serosa-lined Tunnel, and Quality of Life with a Cross-folded Ileal Reservoir Combined with an Afferent Tubular Isoperistaltic Segment for Heterotopic Continent Urinary Diversion: An Observational Long-term Cohort Analysis
Furrer, MA; Noser, L; Lyttwin, B; Kiss, B; Thomas, BC; Bosshard, P; Wuthrich, PY; Studer, UE; Burkhard, FC
(2021), Eur. Urol. Focus, 869-876
Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
Cumberbatch, M; Condon, B; Lawrentschuk, N; Murphy, DG
(2021), Eur. Urol., 319-320
Re: Enzalutamide and Survival in Non-metastatic Castration-resistant Prostate Cancer
Bagguley, D; Ong, S; Lawrentschuk, N; Murphy, DG
(2021), Eur. Urol., 320-321
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial
Cardet, RED; Hofman, MS; Segard, T; Yim, J; Williams, S; Francis, RJ; Frydenberg, M; Lawrentschuk, N; Murphy, DG; Lourenco, RD
(2021), Eur. Urol., 413-418
Original Research Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival
Chow, K; Bedo, J; Ryan, A; Agarwal, D; Bolton, D; Chan, Y; Dundee, P; Frydenberg, M; Furrer, MA; Goad, J; Gyomber, D; Hanegbi, U; Harewood, L; King, D; Lamb, AD; Lawrentschuk, N; Liodakis, P; Moon, D; Murphy, DG; Peters, JS; Ruljancich, P; Verrill, CL; Webb, D; Wong, LM; Zargar, H; Costello, AJ; Papenfuss, AT; Hovens, CM; Corcoran, NM
(2021), Eur. J. Cancer, 440-450
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
Merriel, SWD; Moon, D; Dundee, P; Corcoran, N; Carroll, P; Partin, A; Smith, JA; Hamdy, F; Moore, C; Ost, P; Costello, T
(2021), BMC Urol.